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We evaluated the safety and efﬁcacy of standard-dose yttrium-90 (Y90) ibritumomab tiuxetan combined with
high-dose BEAM (carmustine, etoposide, cytarabine, and melphalan) after ﬁrst-line induction treatment in
young patients with poor prognoses diffuse large B cell lymphoma (DLBCL) (clinicaltrials.gov: NCT00689169).
Seventy-ﬁve high-risk (2 International Prognostic Index [IPI] factors) consecutive DLBCL patients (65 years
old) in complete remission (CR) or partial remission (PR) after rituximab chemotherapy were treated with Y90
ibritumomab tiuxetan and BEAM regimen followed by autologous stem cell transplantation (ASCT). The
median follow-up was 34 months. Of the 75 patients, 71 underwent ASCT and were eligible for analysis.
Median time to reach a neutrophil count of >500/mL and platelet count of >20,000/mL was 11 days. Mucositis
3 (51%) occurred in most patients. Other adverse events were similar to those seen with BEAM alone. The
overall response rate was 86%; 59 patients (83%) achieved a CR or unconﬁrmed CR. The 2-year event-free
survival (EFS), overall survival (OS), and disease-free survival were 79%, 83%, and 91%, respectively. Disease
status (CR/PR) and positron emission tomography (PET) ﬁndings before transplantation did not predict
treatment failure. The IPI (2 versus >2) and maximum tumor diameter of 10 cm at diagnosis appeared to be
prognosis factors for OS but not for EFS. Adding Y90 ibritumomab tiuxetan to BEAM is safe and does not
increase transplantation-related toxicity. First-line consolidation with Y90 ibritumomab tiuxetan and high-
dose chemotherapy induced high rates of EFS and OS in poor-prognosis patients with DLBCL, regardless of
PET status after induction treatment and warrants a randomized study.
 2014 American Society for Blood and Marrow Transplantation.dgments on page 1910.
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ty for Blood and Marrow Transplantation.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most com-
mon subtype of aggressive lymphoma, accounting for 31% of
newly diagnosed non-Hodgkin lymphoma. Outcomes of
C. Fruchart et al. / Biol Blood Marrow Transplant 20 (2014) 1905e19111906DLBCL have improved with the addition of rituximab [1], but
further progress is needed for poor-prognosis patients
because the results are far from satisfactory. The 3-year
event-free survival (EFS) ranges from approximately 70% in
patients with 2 adverse prognostic factors to 50% in patients
with 3 to 5 factors [2,3], according the International Prog-
nostic Index (IPI) [4]. Results from the Collaborative Trial in
Relapses Aggressive Lymphoma showed that only 21% of
patients previously treated with rituximab achieved durable
remission after salvage therapies [5], demonstrating that
improvement in ﬁrst-line treatment in high-risk (IPI 2)
patients with DLBCL is a crucial issue.
Data for young patients with at least 2 adverse prognostic
factors treated with R-ACVBP (rituximab, doxorubicine,
cyclophosphamide, vinblastine, bleomycine, and predni-
sone) and upfront consolidation with high-dose chemo-
therapy (HDT) followed by autologous stem cell
transplantation (ASCT) showed a 4-year progression-free
survival (PFS) rate of 76% [6]. Despite controversy, recent
randomized studies have conﬁrmed these encouraging re-
sults and suggested that high-dose BEAM (carmustine, eto-
poside, cytarabine, and melphalan) followed by ASCT
resulted in a signiﬁcantly higher PFS than standard dos-
eedense chemotherapy, especially in patients with more
than 2 IPI factors responding to ﬁrst-line therapy containing
rituximab [7,8]. Compared with immunotherapy alone,
radioimmunotherapy (RIT) provides the added advantages of
radioisotope emission, which acts over a multicellular range
and, thereby, distributes the radiation more uniformly
throughout the malignant tissue. Yttrium-90 (Y90) ibritu-
momab tiuxetan (Zevalin, Spectrum Pharmaceuticals; Irvine,
CA) is a radiolabeled monoclonal antibody approved for
treatment of rituximab-relapsed/refractory CD20 follicular
B cell lymphoma [9]. Several studies have shown that Zevalin
(Spectrum) is also effective in aggressive lymphomas [10,11].
At the recommended dose of .4 mCi/kg, Y90 ibritumomab
tiuxetan therapy is well tolerated, with myelosuppression as
the only dose-limiting factor. Its good tolerability allows for
its use in combination with high-dose myeloablative regi-
mens. The ﬁrst studies in heavily pretreated patients
demonstrated that the addition of Y90 ibritumomab tiuxetan
does not increase toxicities over those in patients treated
with standard BEAM [12-14]. Y90 ibritumomab tiux-
etanebased conditioning has shown a relapse incidence
similar to that of total body irradiation but with lower
toxicity and better survival [15].
As a component of pretransplantation conditioning regi-
mens, Y90 ibritumomab tiuxetan is an effective option for
enhancing clinical outcomes when combined with HDT fol-
lowed by ASCT, and it can potentially spare patients from
radiotherapy or total body irradiation. We conducted a pro-
spective phase 2 trial that was designed to allow for an
increased number of patients to be studied for toxicities and
to evaluate the efﬁcacy in poor-prognosis DLBCL patients
with a high risk of relapse occurring mostly in the ﬁrst
2 years after transplantation.MATERIALS AND METHODS
Eligibility
Patients from 18 to 65 years old at diagnosis with pathologically proven
CD20þ DLBCL (World Health Organization classiﬁcation) with 2 or more IPI
factors were eligible for this study. All patients were included after R-CHOP
(rituximab, doxorubicine, cyclophosphamide, vincristine, and prednisone)
(4 to 6 cycles) or R-ACVBP (rituximab, doxorubicine, cyclophosphamide,
vinblastine, bleomycine, and prednisone) (4 cycles) if they were chemo-
sensitive (complete remission [CR], unconﬁrmed CR [CRu], or partialremission [PR]), according to the 1999 International Workshop Criteria [16].
Positron emission tomography (PET) scans interpreted according to the
consensus criteria of the International Harmonization Project (IHP) [17]
were required before transplantation, but they were not decisional. All pa-
tients had sufﬁcient peripheral blood stem cells harvested before study
entry (3  106 CD34 cells/kg). Additional requirements included a World
Health Organization performance status of 0 or 1; seronegativity for human
immunodeﬁciency virus, hepatitis B, and hepatitis C; no serious active dis-
ease or comorbid medical conditions; creatinine level of <2.5 times the
upper normal limit; bilirubin level of <30 mmoL/L; transaminase levels of
<2.5 times the upper normal limit; adequate pulmonary function; and a left
cardiac ejection fraction of >50%. The exclusion criteria included other
lymphoma diagnoses, histological transformation in diffuse large cell from a
low-grade B cell lymphoma, involvement of the central nervous system,
bone marrow inﬁltration before transplantation, or poor bone marrow
reserve deﬁned by a neutrophil count of <1.5 Giga/l or platelet count of
<100 Giga/l. All patients had previously provided written informed consent
approved by local ethical committees in accordance with the Declaration of
Helsinki.
Study Design
This prospective phase 2 open-label multicenter study was designed to
assess the safety and efﬁcacy of a preparative regimen comprising Y90
ibritumomab tiuxetan (Zevalin, Spectrum) and high-dose BEAM followed by
ASCT after ﬁrst-line treatment containing rituximab in patients with poor-
risk DLBCL. A screening examination was performed before registration
and included a clinical examination, staging of the disease with computed
tomography, bone marrow biopsy (if positive at diagnosis), ﬂuorodeox-
yglucose (FDG)-PET scanning, and laboratory testing. A central review of the
histological diagnosis was performed for each patient enrolled in the trial.
Pathological specimens of 49 of 75 patients with histological material
available at diagnosis were more extensively analyzed to classify the tumor
biopsy specimens into germinal center B cellelike (GCB) or non-GCB sub-
types as previously published by Hans et al. [18]. The expression of addi-
tional biological markers, such as BCL2 oncoprotein, was determined by
immunohistochemistry. Immunostaining was performed on either full
slides or tissue microarrays and reviewed until consensus by 2 pathologists
at the Lymphoma Study Association (LYSA) Center of Pathology.
All adverse events that occurred during the study treatment or follow-
up periods were graded using the Common Terminology Criteria for
Adverse Events version 3.0. Patients were required to undergo formal dis-
ease assessment 3 months after ASCT by computed tomography. A PET scan
was performed if positive before ASCT. After day 100, disease assessment
was performed every 3 months for 2 years, then every 6 months for 3 years.
The expected total study period was 5 years.
Treatment
On day -21, patients received an infusion of rituximab (250 mg/m2), and
on day -14, patients received a dose of rituximab (250 mg/m2) followed by
Y90 ibritumomab tiuxetan. The exact dose of Y90 ibritumomab tiuxetan was
based on the patient’s weight during the baseline evaluation and platelet
count 3 days before Zevalin (Spectrum) administration. If the platelet count
was 150 G/L, then .4 mCi/kg (15 MBq/kg) of Y90 ibritumomab tiuxetan was
administered; if the platelet count was100 Giga/l, then .3 mCi/kg (11MBq/
kg) of Y90 ibritumomab tiuxetan was administered. A maximum dose of
32 mCi of Y90 ibritumomab tiuxetan was administered to those patients
whose body weight exceeded 80 kg. On days -7 to 2, high-dose BEAM was
administered based on the adjusted ideal body weight (carmustine at
300 mg/m2 on day 7, etoposide at 100 mg/m2, cytarabine at 200 mg/m2
twice daily on days 6 to 3, and melphalan at 140 mg/m2 on day 2) (Z-
BEAM). Peripheral blood stem cells were infused on day 0 according to
institution protocol. After ASCT, hematopoietic growth factor support could
be given according to local policy. Supportive treatments in the form of
hydration, antiemetics, antimicrobial prophylaxis, blood component ther-
apy, and nutritional supportive care were administered according to the
standard use in each center.
Statistics
Patients’ results were analyzed on an intent-to-treat (ITT) and per-
protocol basis. All time-to-events endpoints were assessed both from date
of inclusion and from date of transplantation. The primary endpoint was EFS
and was used to assess sample size. In previous studies, 2-year EFS was
estimated to 70%. We estimated the 2-year EFS of Z-BEAM to 85%. A sample
size of 75 patients, recruited over 3 years and followed for a minimum of
1 year, will provide 80% power at the overall 5% (2-sided) signiﬁcance level
to detect a 2-year EFS above 70%. Event is deﬁned as death of any cause,
relapse in complete responders, progression during or after treatment, and
therapy changes during allocated treatment. The overall response rate, CR,
Table 1
Patient Characteristics (N ¼ 75)
Characteristic Value
Age, median (range), yr 49 (19-64)
Gender
Male 32 (43)
Female 43 (57)
IPI score
2 28 (37)
3-5 47 (63)
Bulky
<10 cm 46 (62)
10 cm 29 (38)
Mediastinal bulk >7 cm
No 55 (73)
Yes 20 (27)
Induction regimen
R-CHOP 36 (48)
R-ACVBP 39 (52)
Disease status at transplantation
CR/Cru 63 (84)
PR 12 (16)
PET before transplantation
Negative 54 (72)
Positive 21 (28)
R-CHOP indicates rituximab, doxorubicine, cyclophosphamide, vincristine,
and prednisone; R-ACVBP, rituximab, doxorubicine, cyclophosphamide,
vinblastine, bleomycine, and prednisone.
Data presented are n (%), unless otherwise indicated.
Figure 1. Event-free (A) and overall survival (B) after inclusion (ITT).
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Criteria at day 100 after ASCT. Disease-free survival (DFS) was calculated as
the duration from the date of CR/CRu after ASCT to the date of the ﬁrst event.
To analyze which variables affect outcome after transplantation, the
following factors determined at diagnosis or at transplantation were
included in the univariate analysis: IPI (2 versus 3 to 5), maximum tumor
diameter (<10 versus 10 cm), bulky mediastinal involvement (7 cm),
type of induction regimen, level of BCL2 expression (<50% versus 50%),
GCB versus non-GCB subtype, disease status (CR-CRu versus PR), and PET
results before transplantation.
Statistical tests were 2-sided and performed using a 5% level of signiﬁ-
cance. The 95% conﬁdence intervals (CIs) were also calculated when
considered relevant. Survival curves were estimated with the Kaplan-Meyer
method. For prognostic factors, survival endpoints were analyzed using the
log-rank test and Cox model for corresponding estimation of hazard ratios.
All statistical analyses were carried out with SAS 9.1.3 software (SAS Insti-
tute, Cary, NC).RESULTS
A total of 75 patients were enrolled in this study from
August 21, 2007 to December 12, 2008. After centralized
pathologic review, ﬁnal histologic diagnoses were conﬁrmed
in all cases. Four premature withdrawals (5%) because of
progressionwere observed. Seventy-three patients receiving
at least 1 injection of study treatment were eligible for ITT
analysis and 71 patients who underwent ASCT were eligible
for per protocol analysis. The median duration of follow-up
was 34 months. Patient characteristics are presented in
Table 1; the median age at inclusion was 49 years (range, 19
to 64 years), with 91% of patients 60 years old.Efﬁcacy
According to the deﬁnition of events, 17 patients (23%)
presented with an event, 16 patients with progression/
relapse, and 1 patient with a death without progression. A
total of 14 patients died: 13 deaths were related to lym-
phoma and 1 was a toxic death. On ITT analysis, the 2-year
EFS was 77% (95% CI, 65% to 85%) and the 2-year OS was
81% (95% CI, 70% to 88%) (Figure 1). Of the 71 patients who
underwent ASCT, 59 (83%) achieved CR or CRu 3months after
transplantation. Two responded partially, leading to anoverall response rate of 86%. After transplantation, 14 pa-
tients experienced progression or relapse and 1 patient died
of toxic death. On per protocol analysis, 2-year EFS was 79%
(95% CI, 67% to 88%), 2-year OS was 83% (95% CI, 70% to 88%),
and 2-year DFSwas 91% (95% CI, 80% to 96%). Because no new
treatment for lymphoma was initiated, the PFS was equiva-
lent to the EFS.
Univariate analysis, presented in Table 2, identiﬁed an IPI
status of >2 and a maximum tumor diameter of 10 cm as
adverse prognostic factors for OS. The 2-year OS was 96% in
patients with an IPI of 2 and 75% in patients with an IPI of 3
to 5 (P ¼ .02). OS was 91% in patients with a tumor diameter
of <10 cm and 70% in patients with a tumor diameter of
10 cm (P ¼ .02). We found no signiﬁcant difference be-
tween positive PET versus negative PET for EFS (79% for
both groups) or OS (95% and 79%, respectively) (P ¼ .135). Of
the 19 patients with positive PET ﬁndings before trans-
plantation, 12 (63%) changed to negative after ASCT, 4
remained positive (no biopsy was performed), and 3 were
not evaluated. Three patients (16%) with positive pre-ASCT
PET ﬁndings developed recurrent disease, 1 had positive
post-ASCT PET ﬁndings, 1 had negative post-ASCT PET
ﬁndings, and 1 was not documented. The pre-
transplantation status according 1999 criteria (CR/CRu
versus PR) had no signiﬁcant effect on EFS or OS. Of the 12
patients who underwent ASCT during the ﬁrst PR period, 7
(58%) converted to CR and 3 had progressive disease.
Neither BCL2 expression of 50% nor non-GCB subtype
affected the prognosis. There were no differences in medi-
astinal involvement or type of induction regimen.
Table 2
Univariate Analysis of Prognostic Factors for Two-Year EFS and OS Performed on the Patients who Received Z-BEAM followed by ASCT
Parameters n Event Two-Year EFS (%) P Value Death Two-Year OS (%) P Value
Overall Population 71 15 79 12 83
IPI
2 27 3 89 .09 1 96 .02
3-5 44 12 73 11 75
Maximal tumor diameter
<10 cm 44 7 84 .13 4 91 .02
10 cm 27 8 70 8 70
Mediastinal involvement
No 51 13 75 .17 10 80 .37
Yes 20 2 70 2 90
Disease status
CR/CRu 59 12 80 .80 10 83 .96
PR 12 3 75 2 83
Induction regimen
R-CHOP 34 6 82 .58 5 85 .63
R-ACVBP 37 9 73 7 81
PET status before transplantation
Negative 52 11 79 .91 11 79 .135
Positive 19 4 79 1 95
Hans algorithm*
CGB 22 8 64 .33 7 68 .56
Non-GCB 21 5 76 5 76
BCL2 expressiony
<50% 21 5 76 .51 4 81 .46
50% 28 9 68 8 71
Bold indicates that the P value is statistically signiﬁcant.
* Done on 43 patients.
y Done on 49 patients.
C. Fruchart et al. / Biol Blood Marrow Transplant 20 (2014) 1905e19111908Multivariate analysis conﬁrmed that an IPI >2 (P ¼ .018)
and tumor mass of <10 cm (P ¼ .010) were independent
prognostic factors with hazard ratios of 4.67 (95% CI, 1.30 to
16.66) and 3.71 (95% CI, 1.37 to 9.90), respectively (Figure 2).Figure 2. Overall survival according to the IPI (A) and maximum tumor
diameter of 10 cm (B).Engraftment and Safety
The median number of CD34 cells infused was 6.2  106/
kg (range, 2.95 to 34.2). Granulocyte counts above .5  109/L
and stable platelet counts above 20  109/L were both
reached after a median of 11 days (ranges, 9 to 378 and 9 to
26 days, respectively). The median number of units of red
blood cell transfusions was 2 (range, 0 to 20), and themedian
number of platelet transfusions was 3 (range, 0 to 15). The
median time to discharge was 16 days (range, 5 to 50).
Grade 3 nonhematologic toxicities are presented in
Table 3. Mucositis occurred in 36 patients (51%), pneumonia
in 6 patients, and diarrhea in 4 patients. Other adverse events
were usually mild to moderate in severity. One patient died
of septic shock 14 days after transplantation. All other pa-
tients recovered from the early transplantation-related
toxicity.
DISCUSSION
To date, this is the ﬁrst prospective phase 2 study to
evaluate the safety and efﬁcacy of standard-dose Y90 ibritu-
momab tiuxetan followed by high-dose BEAM and ASCT for
upfront consolidation in patients with poor prognosis, 2 or
more IPI factors, and DLBCL responding to ﬁrst-line therapyTable 3
Nonhematologic Toxicity of Z-BEAM followed by ASCT in Patients with Poor-
Risk DLBCL
Toxicity Grade 1-2 Grade 3 Total
Mucositis 21 (29) 36 (51) 57 (80)
Infection* 5 (7) 6 (8) 11 (15)
Pulmonary 9 (13) 6 (8) 15 (21)
Diarrhea 45 (64) 4 (6) 49 (70)
Renal 9 (13) 2 (3) 11 (16)
Skin 25 (36) 1 (1) 26 (37)
Cardiac 11 (16) 1 (1) 12 (17)
Hepatic 23 (32) 0 23 (32)
Data presented are n (%).
* Not including uncomplicated neutropenic fever.
C. Fruchart et al. / Biol Blood Marrow Transplant 20 (2014) 1905e1911 1909containing rituximab. Although the best way to select pa-
tients for high-dose consolidationwith ASCT is still in debate,
recent randomized study suggested that only patients
belonging to the high-risk group could beneﬁt from it [8]. We
wanted to investigate if a conditioning regimen with Y90
ibritumomab tiuxetan and high-dose BEAM was highly
effective to reduce the relapse rate. For the 71 patients who
received the Z-BEAM regimen followed by ASCT, the 2-year
EFS and OS rates were 79% and 83%, respectively; 89% and
96% in patients with an IPI of 2, and 73% and 75% for 44
patients with an IPI of 3 to 5.
High-dose BEAM followed by ASCT is considered to be a
relevant option for upfront consolidation in patients with
poor-risk aggressive DLBCL with at least 2 or more IPI
adverse prognostic factors [19,20], but there was substantial
controversy regarding the place and timing of this consoli-
dation [21,22]. In the rituximab era, phase 2 studies evalu-
ating BEAM plus ASCT as consolidation in patient responding
to ﬁrst-line therapy provided encouraging results [23,24].
The LNH 2003-03 trial reported by the Groupe d’Étude des
Lymphomes de l’Adulte (GELA) [6] included 208 patients
with DLBCL with an age-adjusted IPI of 2 (157 patients) and 3
(46 patients). The 4-year PFS and OS were estimated at 76%
and 78%, respectively, with no difference between thosewith
a low or high IPI. For this latter group, the PFS and OS were
72% and 75%, respectively. For the 155 patients submitted to
transplantation, the 4-years EFS was 82% (95% CI, 75% to 88%)
85% for PFS, and 90% for OS. Prospective randomized trials
have reported conﬂicting results. The German study group
found that R-MegaCHOEP, 3 courses of high-dose chemo-
therapy supported by stem cells infusion, given as part of
induction regimen, was not superior to conventional
R-CHOEP (rituximab, doxorubicine, cyclophosphamide,
vincristine, etoposide, and prednisone). The 3-year EFS was
estimated at 61% in the high-dose arm [25]. Preliminary re-
sults of the GOELAMS 075 randomized trial did not show
difference between R-CHOP14 and HDT/ASCT in young
adults with DLBCL [26]. However, their study included pa-
tients with low-risk IPI factors and interim PET was deci-
sional. The Fondazione Italiana Linfomi (FIL) group compared
2 rituximab dose-dense treatments (R-CHOP14 versus R-
megaCHOP14) followed or not by BEAM with ASCT [7].
Consolidationwith HDT/ASCT resulted in a 3-year PFS of 70%
versus 59% in the control arm. The Southwest Oncology
Group reported similar ﬁndings in a randomized trial eval-
uating upfront ASCT in patients with chemosensitive
aggressive lymphoma. The 2-year PFS was 69% in the trans-
plantation arm and 55% in the control arm for the whole
population. The difference was especially pronounced in the
high-risk subgroup (75% versus 41%), but it was not signiﬁ-
cant in the subset of high-intermediate risk (66% versus 63%).
Similar patterns were observed among patients with B cell
lymphoma who were treated with R-CHOP: the 2-year PFS
was 73% in the transplantation arm and 63% in the control
arm [8]. When comparing our results to the transplantation
arms published by Fitoussi or Stiff, the beneﬁt of Z-BEAM is
uncertain and would need a randomized study.
After transplantation, we observed a PR/CR conversion
rate of 58% and PET became negative in 12 (63%) patients,
suggesting that Z-BEAMmight improve the remission status,
which is 1 of the main predictors of increased survival in
DLBCL. Y90 ibritumomab in combination with HDT followed
by ASCT is reportedly effective in heavily pretreated patients
with non-Hodgkin lymphoma [13,27]. Krishnan et al.
administered Z-BEAM as consolidation in 60 patients withpoor-risk NHL of various histologies [13]. The estimated 2-
year PFS and OS for 20 DLBCL were 68% and 89%, respec-
tively. Seven of 10 patients in PR converted to CR after
transplantation. Briones et al. showed that 60% of patients
with refractory DLBCL obtained a complete response with
negative PET-CT after Z-BEAM [28]. In a randomized study
including relapsed/refractory aggressive B cell lymphoma,
Shimoni et al. found a 2-year PFS of 59% and 37% in the Z-
BEAM and BEAM arms, respectively (P ¼ .20), and 2-year OS
of 91% and 62%, respectively (P ¼ .05), suggesting that Z-
BEAM has a survival advantage over BEAM alone [29].
However, the number of patients was still small. In their
prospective randomized phase 3 study including 224 pa-
tients, Vose et al. did not see a difference in relapse of DLBCL
between rituximab BEAM and an 131 iodine tositumomab
conditioning regimen, raising the question of the superiority
of this approach [30].
We observed 14 relapses, and most of them occurred
early after transplantation. For patients who achieved CR/
CRu 3 months after ASCT, the DFS was high (91%). We found
that bulky disease had an adverse prognostic effect
(Figure 2B). The negative impact of a maximal tumor diam-
eter of >10 cm has been demonstrated in young patients
with good prognosis DLBCL [31]. We observed that the EFS
rates in our higher-risk patients with bulky disease receiving
Z-BEAM (70%; 95% CI, 49.4% to 83.9%) appeared relatively
close to those obtained in low-risk patients treated with R-
CHOP followed by additional radiotherapy (78.3%; 95% CI,
71.1% to 86.2%). FDG-PET performed before ASCT appears to
be a useful tool to predict treatment failure in refractory/
relapse lymphomas, but few data are available in ﬁrst-line
therapy [32]. Surprisingly, PET ﬁndings before trans-
plantation did not negatively inﬂuence the outcome in our
experience. Most patients converted from positive FDG-PET
to negative FDG-PET after ASCT, suggesting that the condi-
tioning regimen might play a role in overcoming drug
resistance. However, we did not perform directed biopsy to
conﬁrm the persistence of the lymphoma, and we cannot
exclude some false positivity [33]. We used visual assess-
ment according to the IHP criteria. Although IHP was usually
used, it was established to determine the remission status at
the end of treatment. Other analysis methods have also been
developed, speciﬁcally, interim-PET (I-PET) using visual
assessment with a 5-point scale (ie, the Deauville criteria)
[34] and semiquantitative evaluation based upon the differ-
ences in the standardized uptake value from baseline to I-
PET [35]. Casanovas reported that analysis of the maximal
standardized uptake value reduction (DSUVmax) between
baseline and PET4 in unfavorable, untreated DLBCL appeared
to be better than visual analysis to identify theworst group of
patients who experienced induction failure or early relapse
[36]. We did not ﬁnd a negative impact of high BCL2
expression or a non-GCB phenotype determined by immu-
nohistochemistry, according to the Hans algorithm. Despite
controversy, the Hans algorithm is used daily to stratify
DLBCL into favorable GCB and unfavorable non-GCB pheno-
types. Intensiﬁed chemotherapy with rituximab possibly
improves survival in younger patients with nongerminal
DLBCL compared with standard R-CHOP [37]. In a retro-
spective study of patients with DLBCL treated with ACST as
ﬁrst-line therapy, Gu et al. suggested that the cell of origin
fails to predict survival [38]. The prognostic relevance of BCL2
is more complex. Evaluation performed by the Lunenburg
Lymphoma Biomarker Consortium concluded that BCL2
alone has marginal signiﬁcance [39].
C. Fruchart et al. / Biol Blood Marrow Transplant 20 (2014) 1905e19111910We chose a ﬁxed standard dose of .4 mCi/kg (15 MBq/kg),
approved in the European Union without the necessity for
prior imaging. We conﬁrmed that adding Y90 ibritumomab to
BEAM is safe without an increase in transplantation-related
toxicity or delayed engraftment. As expected, the major
nonhematologic toxicity was represented by severe mucositis
(51%), which ranged from 35% to 68% in previous trials with a
trend toward a higher incidence after Z-BEAM [29]. So far, no
secondary malignancies occurred, but long-term follow-up is
needed for a complete safety report. Previous analysis in pa-
tients treated with Y90 ibritumomab did not show an
increased risk of secondary malignancies [40]. Dose-escalated
Y90elabeled ibritumomab tiuxetan may be safely combined
with BEAM and has the potential to be more effective than
standard dose, but it requires careful dosimetry [14].
To conclude, the favorable efﬁcacy and tolerability proﬁle
of targeted RIT with Y90-labeled ibritumomab tiuxetan
makes it a promising approach to improve survival in
patients with unfavorable DLBCL. Further randomized
studies are warranted to compare BEAM versus Z-BEAM.
Adequate qualitative or quantitative I-PET imaging combined
with biologic markers should be used to identify subsets of
patients who would beneﬁt from HDT with or without RIT.
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